**Core Concept**
Luteinizing hormone-releasing hormone (LHRH) analogues are a class of medications that act as agonists or antagonists of the gonadotropin-releasing hormone (GnRH) receptor, leading to a decrease in testosterone production. In the context of prostate cancer, these analogues are used to reduce testosterone levels, which slows down or stops the growth of cancer cells.

**Why the Correct Answer is Right**
LHRH analogues, such as leuprolide, goserelin, and buserelin, work by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, leading to an increase in testosterone production. However, with continued administration, these analogues downregulate the GnRH receptors in the pituitary gland, resulting in a decrease in LH and FSH secretion and subsequently a decrease in testosterone production. This reduction in testosterone levels is beneficial in the treatment of prostate cancer, as testosterone promotes the growth of cancer cells.

**Why Each Wrong Option is Incorrect**
* **Option A:** Incorrect because it does not specify a GnRH analogue. While other medications may be used in the treatment of prostate cancer, GnRH analogues are a specific class of medications.
* **Option B:** Incorrect because it is not a commonly used GnRH analogue in the treatment of prostate cancer. While other LHRH analogues may be used, leuprolide is a well-established medication in this context.
* **Option D:** Incorrect because it is not a GnRH analogue. This option may refer to a different class of medications used in the treatment of prostate cancer.

**Clinical Pearl / High-Yield Fact**
LHRH analogues can cause a flare effect, where there is an initial increase in testosterone production before the decrease. This can be problematic in patients with prostate cancer, as it can accelerate tumor growth.

**Correct Answer: C. Leuprolide.**